Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2014


COPD: Novel Therapeutics and Management

20 Oct 2014 - 21 Oct 2014 - London, UK



Bookmark and Share


SMi is proud to present its 6th annual conference on COPD taking place from the 20th - 21st October 2014 in Central London. 

With the global COPD market forecasted to reach a value of $15.6 billion by 2019, COPD 2014 comes at a perfect time to provide the industry with a niche platform for discussion and a forum to learn from key visionaries in the field of COPD. 

The latest instalment in the successful series has evolved to include topical and current sessions, such as Patient Care and The Future of COPD, as well as presenting attendees with in-depth information on exacerbation and comorbidities, ensuring a successful clinical trial design and challenges in drug development and market access. 

“Fast and cost effective development of drugs that help to improve significantly the quality of life of patients requires the intensified collaboration of industry, academia, clinical research and regulators agencies. Working in the field of biomarkers at the interface of pre-clinical and clinical research makes this an everyday requirement. The 6th COPD conference will bring together key opinion leaders from different stakeholders and will therefore foster this collaboration, especially by providing a very focused agenda.” Thomas Schlange, Senior Biomarker Expert, Bayer

KEY SPEAKERS INCLUDE:

  • Marcello Milano, Executive Global Regulatory Affairs, Chiesi
  • Thomas Schlange, Senior Biomarker Expert, Bayer
  • Mercedes Prior, Head of Global Market Access, Almirall
  • Carla Bauer, Investigator, Novartis
  • Jan-Anders Karlsson, CEO, Verona Pharma
  • Ewan Walters, Medical Director, Teva
  • Rosa Lamarca, Head of Clinical Statistics, Almirall
  • Robert Wilson, Consultant Physician Lung Division, Royal Brompton Hospital
  • Abebaw Yohannes, Reader in Physiotherapy, Manchester Metropolitan University
  • Jim & Mary Nelson, Patient, Caregiver, Representatives of COPD Foundation and EFFORTS Online Support Group

WHY ATTEND THIS EVENT:

  • Understand the regulatory aspects of COPD, both from regulatory bodies and the industry
  • Examine the current challenges to modelling exacerbations in COPD using animal models
  • Evaluate COPD and comorbidities
  • Understand the link between COPD and anxiety and depression
  • Review the challenges in clinical trial designs and in drug development
  • Discover the importance of putting the patient at the centre of everything
  • Gain insight from real life story of a lung transplant patient

To register or to download a brochure, visit http://www.smi-online.co.uk/goto/2014copd-conference37.asp

Alternatively contact Fateja Begum on +44 (0) 207 827 6184 or email fbegum@smi-online.co.uk 



Further information
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!